comparemela.com

Latest Breaking News On - Implantable cardiac output management system - Page 2 : comparemela.com

FineHeart S A: Treatment of Severe Heart Failure - AI: FineHeart: ICOMS FLOWMAKER Algorithms Patented in the U S

Severe Heart Failure Treatment: FineHeart Completes its Series B Funding Taking the Total to €21 Million

€6 million of further funds raised in addition to the €15 million in June Clinical trials expected in 2022 FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER

FineHeart S A: Severe Heart Failure Treatment: FineHeart Successfully Raises €15 million Series B funding With Industrial and Independent Investors

The First In Human implantation of the ICOMS FLOWMAKER is assured following this financing FineHeart S.A, a preclinical medical device company that has developed theICOMS FLOWMAKER, an Implantable

FineHeart S A: FineHeart Breaks New Ground With Successful Removal of the ICOMS FLOWMAKER in a 90-day In-vivo Trial

FineHeart S.A: FineHeart Breaks New Ground With Successful Removal of the ICOMS FLOWMAKER in a 90-day In-vivo Trial Easy removal with a beating heart without damage to the myocardium 30 days after implantation Normal heart functioning 60 days after explantation Completely sealed operation with dedicated implant fixation system Quick recovery and short hospital stay Autonomy and free from complications or infection, or structural damage to the heart and vital organs FineHeart S.A a preclinical medical device company that has developed the ICOMS FLOWMAKER, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the successful, simple, and breakthrough implantation and removal of its device in a 90-day in-vivo trial.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.